Akari Therapeutics Plc
AKTX Nasdaq· Pharmaceutical Preparations
Last close · Oct 27, 2026
$8.58
KIRA · Stoqly’s AI analyst, in plain words
- Akari Therapeutics Plc lost $17.3M in fiscal 2025.
Market cap
$1.23T
P/E
—
Revenue
—
Net income
−$17.3M
Free cash flow
—
Operating margin
—
Akari Therapeutics Plc in 30 seconds · fiscal 2025
Does it make a profit?
−$17.3M
No. It lost money last year.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Akari Therapeutics Plc does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 30, 2026
- Legal name
- Akari Therapeutics Plc
- CIK
- 0001541157
Akari Therapeutics Plc · AKTX
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY15 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Net income | −$45.3M | — | −$10.0M | −$19.8M | −$17.3M |
| Diluted EPS | −$0.05 | — | $0.00 | $0.00 | $0.00 |
| Cash | |||||
| Cash from operations | −$5.0M | — | −$16.4M | −$12.6M | −$10.6M |
| Capital expenditure | $0.0M | — | — | — | — |
| Free cash flow | −$5.0M | — | — | — | — |
| Share count change | 896.4% | — | — | 144.0% | 181.8% |
| Debt and strength | |||||
| Cash and short-term investments | $68.9M | $13.3M | $3.8M | $0.0M | $5.2M |
| Shareholders' equity | $48.7M | $1.8M | −$0.2M | $22.2M | $28.3M |
| Current ratio | 3.3x | — | 0.9x | 0.1x | 0.4x |
| Interest coverage | −10.0x | — | — | −88.7x | −172.8x |
| Returns and quality | |||||
| Return on equity | −177.9% | — | −1,281.4% | −179.9% | −68.4% |
| Return on tangible equity | −93.1% | — | — | −143.4% | −86.9% |
| Altman Z'' | 1.4 | — | −196.6 | −20.2 | −19.9 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Akari Therapeutics Plc · AKTX
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $8.58 a share, the company is worth $1.23T.
Source: SEC EDGAR XBRL filings (CIK 0001541157). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.